Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886540 | 0.78 | ADRA2A (0.39) | — | |
| SCHEMBL2971715 | 0.78 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2961660 | 0.78 | CHRNB2 (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL10463741 | 0.69 | LMNA (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1243243 | 0.67 | CCR5 (0.47) | PNMTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL8007981 | 0.67 | CCR5 (0.47) | PNMTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL13250365 | 0.67 | CCR5 (0.47) | PNMTCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20758331 | 0.65 | CCR5 (0.32) | — | |
| SCHEMBL1545962 | 0.64 | CCR5 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20384023 | 0.63 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767814-B2 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-20060223840-A1 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION | 2006-10-05 | — | — | US | disclosed |
| US-7087749-B2 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2005090350-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203123-A1 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203123-A1 | Substituted piperidine compounds and methods of their use | OPRM1, OPRD1, OPRK1 | PNMT 38/4885CHRNB2 342/4885CHRNB4 151/4885 |
| US-20060223840-A1 | Substituted piperidine compounds and methods of their use | OPRM1, OPRD1, OPRK1 | PNMT 38/4885CHRNB2 342/4885CHRNB4 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.